PAPP‐A: a promising therapeutic target for healthy longevity

Pregnancy‐associated plasma protein‐A (PAPP‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased li...

Descripción completa

Detalles Bibliográficos
Autores principales: Conover, Cheryl A., Oxvig, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334524/
https://www.ncbi.nlm.nih.gov/pubmed/28035757
http://dx.doi.org/10.1111/acel.12564
_version_ 1782511863493296128
author Conover, Cheryl A.
Oxvig, Claus
author_facet Conover, Cheryl A.
Oxvig, Claus
author_sort Conover, Cheryl A.
collection PubMed
description Pregnancy‐associated plasma protein‐A (PAPP‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP‐A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP‐A as a therapeutic target to promote healthy longevity.
format Online
Article
Text
id pubmed-5334524
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53345242017-04-01 PAPP‐A: a promising therapeutic target for healthy longevity Conover, Cheryl A. Oxvig, Claus Aging Cell Reviews Pregnancy‐associated plasma protein‐A (PAPP‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP‐A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP‐A as a therapeutic target to promote healthy longevity. John Wiley and Sons Inc. 2016-12-29 2017-04 /pmc/articles/PMC5334524/ /pubmed/28035757 http://dx.doi.org/10.1111/acel.12564 Text en © 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Conover, Cheryl A.
Oxvig, Claus
PAPP‐A: a promising therapeutic target for healthy longevity
title PAPP‐A: a promising therapeutic target for healthy longevity
title_full PAPP‐A: a promising therapeutic target for healthy longevity
title_fullStr PAPP‐A: a promising therapeutic target for healthy longevity
title_full_unstemmed PAPP‐A: a promising therapeutic target for healthy longevity
title_short PAPP‐A: a promising therapeutic target for healthy longevity
title_sort papp‐a: a promising therapeutic target for healthy longevity
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334524/
https://www.ncbi.nlm.nih.gov/pubmed/28035757
http://dx.doi.org/10.1111/acel.12564
work_keys_str_mv AT conovercheryla pappaapromisingtherapeutictargetforhealthylongevity
AT oxvigclaus pappaapromisingtherapeutictargetforhealthylongevity

Ejemplares similares